# A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

> **NCT05585632** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 392 (actual)

## Conditions studied

- SARS-CoV-2
- Influenza
- RSV

## Interventions

- **BIOLOGICAL:** mRNA-1010
- **BIOLOGICAL:** mRNA-1345
- **BIOLOGICAL:** mRNA-1273.214
- **BIOLOGICAL:** mRNA-1045
- **BIOLOGICAL:** mRNA-1230

## Key facts

- **NCT ID:** NCT05585632
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-14
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05585632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05585632, "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05585632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*